- Home
- WRB vs ILMN Comparison
WRB vs ILMN Comparison
Compare WRB & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WRB | ILMN |
|---|---|---|
| Founded | 1967 | 1998 |
| Country | United States | United States |
| Employees | 8804 | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7B | 24.6B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | WRB | ILMN |
|---|---|---|
| Price | $70.11 | $175.19 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 16 | 17 |
| Target Price | $68.86 | ★ $124.24 |
| AVG Volume (30 Days) | ★ 2.0M | 2.0M |
| Earning Date | 04-21-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | N/A | ★ 0.87 |
| Revenue | N/A | ★ $4,343,000,000.00 |
| Revenue This Year | $5.18 | $6.47 |
| Revenue Next Year | $4.95 | $5.58 |
| P/E Ratio | ★ $15.91 | $189.57 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $62.87 | $88.00 |
| 52 Week High | $78.96 | $177.22 |
Technical Indicators
Market Signals| Indicator | WRB | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 63.29 | 67.09 |
| Support Level | $65.14 | $116.54 |
| Resistance Level | $71.18 | $177.22 |
| Average True Range (ATR) | 1.37 | 6.77 |
| MACD | 0.25 | -0.24 |
| Stochastic Oscillator | 91.21 | 87.26 |
Price Performance
Historical ComparisonAbout WRB W.R. Berkley Corporation
W.R. Berkley is an insurance holding company with a host of subsidiaries that primarily underwrite commercial casualty insurance. The firm specializes in niche products that include various excess and surplus lines, workers' compensation insurance, self-insurance consulting, reinsurance, and regional commercial lines for small and midsize businesses.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.